{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:50:37Z","timestamp":1770749437975,"version":"3.50.0"},"publisher-location":"Cham","reference-count":111,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031400469","type":"print"},{"value":"9783031400476","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/164_2022_608","type":"book-chapter","created":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T20:02:35Z","timestamp":1661112155000},"page":"35-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Precision Medicine in Therapy of Non-solid Cancer"],"prefix":"10.1007","author":[{"given":"Ines","family":"Schmidts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"608_CR1","doi-asserted-by":"publisher","unstructured":"Abramson JS, Ghosh N, Smith SM (2020) ADCs, BiTEs, CARs, and small molecules: a new era of targeted therapy in non-Hodgkin lymphoma. Am Soc Clin Oncol Educ Book:302\u2013313. https:\/\/doi.org\/10.1200\/edbk_279043","DOI":"10.1200\/edbk_279043"},{"key":"608_CR2","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1074\/jbc.272.4.2042","volume":"272","author":"S Aizawa","year":"1997","unstructured":"Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T (1997) Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem 272:2042\u20132045. https:\/\/doi.org\/10.1074\/jbc.272.4.2042","journal-title":"J Biol Chem"},{"key":"608_CR3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nrd2397","volume":"6","author":"L Altucci","year":"2007","unstructured":"Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H (2007) RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 6:793\u2013810. https:\/\/doi.org\/10.1038\/nrd2397","journal-title":"Nat Rev Drug Discov"},{"key":"608_CR4","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3390\/toxins5081486","volume":"5","author":"A Antignani","year":"2013","unstructured":"Antignani A, Fitzgerald D (2013) Immunotoxins: the role of the toxin. Toxins 5:1486\u20131502. https:\/\/doi.org\/10.3390\/toxins5081486","journal-title":"Toxins"},{"key":"608_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.beha.2017.10.010","volume":"31","author":"PC Arora","year":"2018","unstructured":"Arora PC, Portell CA (2018) Novel therapies for relapsed\/refractory mantle cell lymphoma. Best Pract Res Clin Haematol 31:105\u2013113. https:\/\/doi.org\/10.1016\/j.beha.2017.10.010","journal-title":"Best Pract Res Clin Haematol"},{"key":"608_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","volume":"18","author":"AS Azmi","year":"2021","unstructured":"Azmi AS, Uddin MH, Mohammad RM (2021) The nuclear export protein XPO1 \u2013 from biology to targeted therapy. Nat Rev Clin Oncol 18:152\u2013169. https:\/\/doi.org\/10.1038\/s41571-020-00442-4","journal-title":"Nat Rev Clin Oncol"},{"key":"608_CR7","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1182\/blood.2019004205","volume":"135","author":"P Blombery","year":"2020","unstructured":"Blombery P, Thompson ER, Nguyen T, Birkinshaw RW, Gong JN, Chen X, McBean M, Thijssen R, Conway T, Anderson MA, Seymour JF, Westerman DA, Czabotar PE, Huang DCS, Roberts AW (2020) Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood 135:773\u2013777. https:\/\/doi.org\/10.1182\/blood.2019004205","journal-title":"Blood"},{"key":"608_CR8","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","volume":"26","author":"FZ Cader","year":"2020","unstructured":"Cader FZ, Hu X, Goh WL, Wienand K, Ouyang J, Mandato E, Redd R, Lawton LN, Chen P-H, Weirather JL, Schackmann RCJ, Li B, Ma W, Armand P, Rodig SJ, Neuberg D, Liu XS, Shipp MA (2020) A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med 26:1468\u20131479. https:\/\/doi.org\/10.1038\/s41591-020-1006-1","journal-title":"Nat Med"},{"key":"608_CR9","doi-asserted-by":"publisher","unstructured":"Campbell KS, Cohen AD, Pazina T (2018) Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, Elotuzumab in multiple myeloma. Front Immunol 9. https:\/\/doi.org\/10.3389\/fimmu.2018.02551","DOI":"10.3389\/fimmu.2018.02551"},{"key":"608_CR10","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.2174\/0929867325666181016163110","volume":"27","author":"L Cappellacci","year":"2020","unstructured":"Cappellacci L, Perinelli DR, Maggi F, Grifantini M, Petrelli R (2020) Recent progress in histone deacetylase inhibitors as anticancer agents. Curr Med Chem 27:2449\u20132493. https:\/\/doi.org\/10.2174\/0929867325666181016163110","journal-title":"Curr Med Chem"},{"key":"608_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin J-R, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S (2019) Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 381:727\u2013738. https:\/\/doi.org\/10.1056\/NEJMoa1903455","journal-title":"N Engl J Med"},{"key":"608_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.exphem.2017.07.003","volume":"54","author":"S Charmsaz","year":"2017","unstructured":"Charmsaz S, Scott AM, Boyd AW (2017) Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors. Exp Hematol 54:31\u201339. https:\/\/doi.org\/10.1016\/j.exphem.2017.07.003","journal-title":"Exp Hematol"},{"key":"608_CR13","doi-asserted-by":"publisher","unstructured":"Chatzikonstantinou T, Demosthenous C, Baliakas P (2021) Biology and treatment of high-risk CLL: significance of complex karyotype. Front Oncol 11. https:\/\/doi.org\/10.3389\/fonc.2021.788761","DOI":"10.3389\/fonc.2021.788761"},{"key":"608_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","volume":"20","author":"P Cohen","year":"2021","unstructured":"Cohen P, Cross D, J\u00e4nne PA (2021) Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov 20:551\u2013569. https:\/\/doi.org\/10.1038\/s41573-021-00195-4","journal-title":"Nat Rev Drug Discov"},{"key":"608_CR15","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/leu.2015.29","volume":"29","author":"NCP Cross","year":"2015","unstructured":"Cross NCP, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, Martinelli G, Oppliger Leibundgut E, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, M\u00fcller MC, Hochhaus A (2015) Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 29:999\u20131003. https:\/\/doi.org\/10.1038\/leu.2015.29","journal-title":"Leukemia"},{"key":"608_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739\u2013744. https:\/\/doi.org\/10.1038\/nature08617","journal-title":"Nature"},{"key":"608_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ (2019) Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33:299\u2013312. https:\/\/doi.org\/10.1038\/s41375-018-0357-9","journal-title":"Leukemia"},{"key":"608_CR18","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1002\/med.21578","volume":"39","author":"NR de Almeida","year":"2019","unstructured":"de Almeida NR, Conda-Sheridan M (2019) A review of the molecular design and biological activities of RXR agonists. Med Res Rev 39:1372\u20131397. https:\/\/doi.org\/10.1002\/med.21578","journal-title":"Med Res Rev"},{"key":"608_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien H-F, Wei AH, L\u00f6wenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"608_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","volume":"18","author":"H D\u00f6hner","year":"2021","unstructured":"D\u00f6hner H, Wei AH, L\u00f6wenberg B (2021) Towards precision medicine for AML. Nat Rev Clin Oncol 18:577\u2013590. https:\/\/doi.org\/10.1038\/s41571-021-00509-w","journal-title":"Nat Rev Clin Oncol"},{"key":"608_CR21","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/s1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, K\u00f6ppler H, Kiehl M, S\u00f6kler M, Schlag R, Vehling-Kaiser U, K\u00f6chling G, Pl\u00f6ger C, Gregor M, Plesner T, Trneny M, Fischer K, D\u00f6hner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, B\u00f6ttcher S, Hallek M (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17:928\u2013942. https:\/\/doi.org\/10.1016\/s1470-2045(16)30051-1","journal-title":"Lancet Oncol"},{"key":"608_CR22","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.3390\/cancers12113087","volume":"12","author":"H El Achi","year":"2020","unstructured":"El Achi H, Dupont E, Paul S, Khoury JD (2020) CD123 as a biomarker in hematolymphoid malignancies: principles of detection and targeted therapies. Cancer 12:3087. https:\/\/doi.org\/10.3390\/cancers12113087","journal-title":"Cancer"},{"key":"608_CR23","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1182\/blood.2021013502","volume":"139","author":"B Falini","year":"2022","unstructured":"Falini B, De Carolis L, Tiacci E (2022) How I treat refractory\/relapsed hairy cell leukemia with BRAF inhibitors. Blood 139:2294\u20132305. https:\/\/doi.org\/10.1182\/blood.2021013502","journal-title":"Blood"},{"key":"608_CR24","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/j.clml.2020.12.007","volume":"21","author":"J Feld","year":"2021","unstructured":"Feld J, Silverman LR, Navada SC (2021) Forsaken pharmaceutical: glasdegib in acute myeloid leukemia and myeloid diseases. Clin Lymphoma Myeloma Leuk 21:e415\u2013e422. https:\/\/doi.org\/10.1016\/j.clml.2020.12.007","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"608_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, L\u00f6wenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553\u2013567. https:\/\/doi.org\/10.1016\/j.ccr.2010.11.015","journal-title":"Cancer Cell"},{"key":"608_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjh.14770","volume":"179","author":"MJ Flynn","year":"2017","unstructured":"Flynn MJ, Hartley JA (2017) The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer. Br J Haematol 179:20\u201335. https:\/\/doi.org\/10.1111\/bjh.14770","journal-title":"Br J Haematol"},{"key":"608_CR27","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1056\/NEJMc1402716","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, Racchumi J, Xu G, Wu H, Ma J, Steggerda SM, Coleman M, Leslie C, Wang YL (2014) Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med 370:2352\u20132354. https:\/\/doi.org\/10.1056\/NEJMc1402716","journal-title":"N Engl J Med"},{"key":"608_CR28","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1158\/0008-5472.Can-15-1330","volume":"75","author":"N G\u00fcl","year":"2015","unstructured":"G\u00fcl N, van Egmond M (2015) Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Res 75:5008\u20135013. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-1330","journal-title":"Cancer Res"},{"key":"608_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/2040620716648566","volume":"7","author":"B Hambley","year":"2016","unstructured":"Hambley B, Caimi PF, William BM (2016) Bortezomib for the treatment of mantle cell lymphoma: an update. Ther Adv Hematol 7:196\u2013208. https:\/\/doi.org\/10.1177\/2040620716648566","journal-title":"Ther Adv Hematol"},{"key":"608_CR30","doi-asserted-by":"publisher","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","volume":"8","author":"JA Hartley","year":"2018","unstructured":"Hartley JA, Flynn MJ, Bingham JP, Corbett S, Reinert H, Tiberghien A, Masterson LA, Antonow D, Adams L, Chowdhury S, Williams DG, Mao S, Harper J, Havenith CEG, Zammarchi F, Chivers S, van Berkel PH, Howard PW (2018) Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Sci Rep 8:10479. https:\/\/doi.org\/10.1038\/s41598-018-28533-4","journal-title":"Sci Rep"},{"key":"608_CR31","doi-asserted-by":"publisher","unstructured":"Hashmi H, Darwin A, Nishihori T (2021) Therapeutic roles of antibody drug conjugates (ADCs) in relapsed\/refractory lymphomas. Hematol Oncol Stem Cell Ther. https:\/\/doi.org\/10.1016\/j.hemonc.2021.07.002","DOI":"10.1016\/j.hemonc.2021.07.002"},{"key":"608_CR32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3324\/haematol.2016.142877","volume":"101","author":"R Hehlmann","year":"2016","unstructured":"Hehlmann R (2016) Innovation in hematology. Perspectives: CML 2016. Haematologica 101:657\u2013659. https:\/\/doi.org\/10.3324\/haematol.2016.142877","journal-title":"Haematologica"},{"key":"608_CR33","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/jco.2002.20.6.1692","volume":"20","author":"MC Heinrich","year":"2002","unstructured":"Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692\u20131703. https:\/\/doi.org\/10.1200\/jco.2002.20.6.1692","journal-title":"J Clin Oncol"},{"key":"608_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP (2014) Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer 14:219\u2013232. https:\/\/doi.org\/10.1038\/nrc3702","journal-title":"Nat Rev Cancer"},{"key":"608_CR35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.semcancer.2017.07.009","volume":"51","author":"M Heuser","year":"2018","unstructured":"Heuser M, Yun H, Thol F (2018) Epigenetics in myelodysplastic syndromes. Semin Cancer Biol 51:170\u2013179. https:\/\/doi.org\/10.1016\/j.semcancer.2017.07.009","journal-title":"Semin Cancer Biol"},{"key":"608_CR36","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, Tettero JM, Bachas C, Baer C, B\u00e9n\u00e9 M-C, B\u00fccklein V, Czyz A, Denys B, Dillon R, Feuring-Buske M, Guzman ML, Haferlach T, Han L, Herzig JK, Jorgensen JL, Kern W, Konopleva MY, Lacombe F, Libura M, Majchrzak A, Maurillo L, Ofran Y, Philippe J, Plesa A, Preudhomme C, Ravandi F, Roumier C, Subklewe M, Thol F, van de Loosdrecht AA, van der Reijden BA, Venditti A, Wierzbowska A, Valk PJM, Wood BL, Walter RB, Thiede C, D\u00f6hner K, Roboz GJ, Cloos J (2021) 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party. Blood 138:2753\u20132767. https:\/\/doi.org\/10.1182\/blood.2021013626","journal-title":"Blood"},{"key":"608_CR37","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Sau\u00dfele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"608_CR38","doi-asserted-by":"publisher","unstructured":"Ito S (2020) Proteasome inhibitors for the treatment of multiple myeloma. Cancers (Basel) 12. https:\/\/doi.org\/10.3390\/cancers12020265","DOI":"10.3390\/cancers12020265"},{"key":"608_CR39","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1097\/hs9.0000000000000474","volume":"4","author":"U J\u00e4ger","year":"2020","unstructured":"J\u00e4ger U, Kapitein P, Gribben J (2020) Personalized treatment for hematologic diseases in Europe: An EHA position paper. HemaSphere 4:e474. https:\/\/doi.org\/10.1097\/hs9.0000000000000474","journal-title":"HemaSphere"},{"key":"608_CR40","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1242\/jcs.172775","volume":"128","author":"N Jethwa","year":"2015","unstructured":"Jethwa N, Chung GHC, Lete MG, Alonso A, Byrne RD, Calleja V, Larijani B (2015) Endomembrane PtdIns(3,4,5)P3 activates the PI3K\u2013Akt pathway. J Cell Sci 128:3456\u20133465. https:\/\/doi.org\/10.1242\/jcs.172775","journal-title":"J Cell Sci"},{"key":"608_CR41","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/leu.2015.240","volume":"30","author":"H Jiang","year":"2016","unstructured":"Jiang H, Acharya C, An G, Zhong M, Feng X, Wang L, Dasilva N, Song Z, Yang G, Adrian F, Qiu L, Richardson P, Munshi NC, Tai YT, Anderson KC (2016) SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia 30:399\u2013408. https:\/\/doi.org\/10.1038\/leu.2015.240","journal-title":"Leukemia"},{"key":"608_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/biology10040255","volume":"10","author":"D Lainez-Gonz\u00e1lez","year":"2021","unstructured":"Lainez-Gonz\u00e1lez D, Serrano-L\u00f3pez J, Alonso-Dom\u00ednguez JM (2021) Understanding the hedgehog signaling pathway in acute myeloid leukemia stem cells: a necessary step toward a cure. Biology 10:255. https:\/\/doi.org\/10.3390\/biology10040255","journal-title":"Biology"},{"key":"608_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/ajh.26379","volume":"97","author":"A Lakshman","year":"2022","unstructured":"Lakshman A, Kumar SK (2022) Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update. Am J Hematol 97:99\u2013118. https:\/\/doi.org\/10.1002\/ajh.26379","journal-title":"Am J Hematol"},{"key":"608_CR44","doi-asserted-by":"publisher","unstructured":"Lasica M, Anderson MA (2021) Review of venetoclax in CLL, AML and multiple myeloma. J Pers Med 11. https:\/\/doi.org\/10.3390\/jpm11060463","DOI":"10.3390\/jpm11060463"},{"key":"608_CR45","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2174\/156802612799436687","volume":"12","author":"A le Maire","year":"2012","unstructured":"le Maire A, Alvarez S, Shankaranarayanan P, Lera AR, Bourguet W, Gronemeyer H (2012) Retinoid receptors and therapeutic applications of RAR\/RXR modulators. Curr Top Med Chem 12:505\u2013527. https:\/\/doi.org\/10.2174\/156802612799436687","journal-title":"Curr Top Med Chem"},{"key":"608_CR46","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s12185-021-03126-6","volume":"113","author":"H Lee","year":"2021","unstructured":"Lee H, Basso IN, Kim DDH (2021) Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Hematol 113:632\u2013641. https:\/\/doi.org\/10.1007\/s12185-021-03126-6","journal-title":"Int J Hematol"},{"key":"608_CR47","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.3390\/molecules27072201","volume":"27","author":"C Leonardo-Sousa","year":"2022","unstructured":"Leonardo-Sousa C, Carvalho AN, Guedes RA, Fernandes PMP, Aniceto N, Salvador JAR, Gama MJ, Guedes RC (2022) Revisiting proteasome inhibitors: molecular underpinnings of their development, mechanisms of resistance and strategies to overcome anti-cancer drug resistance. Molecules 27:2201. https:\/\/doi.org\/10.3390\/molecules27072201","journal-title":"Molecules"},{"key":"608_CR48","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1038\/s41375-019-0646-y","volume":"34","author":"N Liebers","year":"2020","unstructured":"Liebers N, Roider T, Bohn J-P, Haberbosch I, Pircher A, Ferstl B, Ebn\u00f6ther M, Wendtner C-M, Dearden C, Follows GA, Ho AD, M\u00fcller-Tidow C, Dreger P, Troussard X, Zenz T, Dietrich S (2020) BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. Leukemia 34:1454\u20131457. https:\/\/doi.org\/10.1038\/s41375-019-0646-y","journal-title":"Leukemia"},{"key":"608_CR49","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri.2016.93","volume":"16","author":"CL Lucas","year":"2016","unstructured":"Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K (2016) PI3K\u03b4 and primary immunodeficiencies. Nat Rev Immunol 16:702\u2013714. https:\/\/doi.org\/10.1038\/nri.2016.93","journal-title":"Nat Rev Immunol"},{"key":"608_CR50","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1182\/blood.2019003722","volume":"135","author":"F Lucas","year":"2020","unstructured":"Lucas F, Larkin K, Gregory CT, Orwick S, Doong TJ, Lozanski A, Lozanski G, Misra S, Ngankeu A, Ozer HG, Sampath D, Thangavadivel S, Yilmaz SA, Rogers KA, Byrd JC, Woyach JA, Blachly JS (2020) Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK\/PLCG2 mutations. Blood 135:2192\u20132195. https:\/\/doi.org\/10.1182\/blood.2019003722","journal-title":"Blood"},{"key":"608_CR51","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/0092-8674(95)90200-7","volume":"83","author":"DJ Mangelsdorf","year":"1995","unstructured":"Mangelsdorf DJ, Evans RM (1995) The RXR heterodimers and orphan receptors. Cell 83:841\u2013850. https:\/\/doi.org\/10.1016\/0092-8674(95)90200-7","journal-title":"Cell"},{"key":"608_CR52","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912\u20131934. https:\/\/doi.org\/10.1126\/science.1075762","journal-title":"Science"},{"key":"608_CR53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13287-021-02283-z","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Tahmasebi S, Rahman HS, Kaigorodov D, Markov A, Yumashev AV, Shomali N, Chartrand MS, Pathak Y, Mohammed RN, Jarahian M, Motavalli R, Motavalli Khiavi F (2021) Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism. Stem Cell Res Ther 12:217. https:\/\/doi.org\/10.1186\/s13287-021-02283-z","journal-title":"Stem Cell Res Ther"},{"key":"608_CR54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11899-021-00619-3","volume":"16","author":"H McMurry","year":"2021","unstructured":"McMurry H, Fletcher L, Traer E (2021) IDH inhibitors in AML-promise and pitfalls. Curr Hematol Malig Rep 16:207\u2013217. https:\/\/doi.org\/10.1007\/s11899-021-00619-3","journal-title":"Curr Hematol Malig Rep"},{"key":"608_CR55","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.3390\/cancers13133214","volume":"13","author":"M Molica","year":"2021","unstructured":"Molica M, Perrone S, Mazzone C, Niscola P, Cesini L, Abruzzese E, de Fabritiis P (2021) CD33 expression and gentuzumab ozogamicin in acute myeloid leukemia: two sides of the same coin. Cancer 13:3214. https:\/\/doi.org\/10.3390\/cancers13133214","journal-title":"Cancer"},{"key":"608_CR56","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1080\/10428194.2016.1247956","volume":"58","author":"AJ Moskowitz","year":"2017","unstructured":"Moskowitz AJ, Horwitz SM (2017) Targeting histone deacetylases in T-cell lymphoma. Leuk Lymphoma 58:1306\u20131319. https:\/\/doi.org\/10.1080\/10428194.2016.1247956","journal-title":"Leuk Lymphoma"},{"key":"608_CR57","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1097\/hs9.0000000000000020","volume":"2","author":"RH Moy","year":"2018","unstructured":"Moy RH, Younes A (2018) Immune checkpoint inhibition in Hodgkin lymphoma. HemaSphere 2:e20. https:\/\/doi.org\/10.1097\/hs9.0000000000000020","journal-title":"HemaSphere"},{"key":"608_CR58","first-page":"1261","volume":"86","author":"L Mu\u00f1oz","year":"2001","unstructured":"Mu\u00f1oz L, Nomded\u00e9u JF, L\u00f3pez O, Carnicer MJ, Bellido M, Avent\u00edn A, Brunet S, Sierra J (2001) Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 86:1261\u20131269","journal-title":"Haematologica"},{"key":"608_CR59","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1038\/s41375-020-0958-y","volume":"34","author":"B Nachmias","year":"2020","unstructured":"Nachmias B, Schimmer AD (2020) Targeting nuclear import and export in hematological malignancies. Leukemia 34:2875\u20132886. https:\/\/doi.org\/10.1038\/s41375-020-0958-y","journal-title":"Leukemia"},{"key":"608_CR60","unstructured":"National Cancer Institute (2022) Drugs approved for different types of cancer. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/cancer-type. Accessed 14 July 2022"},{"key":"608_CR61","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/eji.202049043","volume":"51","author":"JP Nicolay","year":"2021","unstructured":"Nicolay JP, Albrecht JD, Alberti-Violetti S, Berti E (2021) CCR4 in cutaneous T-cell lymphoma: therapeutic targeting of a pathogenic driver. Eur J Immunol 51:1660\u20131671. https:\/\/doi.org\/10.1002\/eji.202049043","journal-title":"Eur J Immunol"},{"key":"608_CR62","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3324\/haematol.2010.025338","volume":"95","author":"D Oscier","year":"2010","unstructured":"Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, Else M, Matutes E, Catovsky D (2010) Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 95:1705\u20131712. https:\/\/doi.org\/10.3324\/haematol.2010.025338","journal-title":"Haematologica"},{"key":"608_CR63","doi-asserted-by":"publisher","unstructured":"Paradzik T, Bandini C, Mereu E, Labrador M, Taiana E, Amodio N, Neri A, Piva R (2021) The landscape of signaling pathways and proteasome inhibitors combinations in multiple myeloma. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13061235","DOI":"10.3390\/cancers13061235"},{"key":"608_CR64","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ajh.26118","volume":"96","author":"A Pardanani","year":"2021","unstructured":"Pardanani A (2021) Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management. Am J Hematol 96:508\u2013525. https:\/\/doi.org\/10.1002\/ajh.26118","journal-title":"Am J Hematol"},{"key":"608_CR65","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M (2020) The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica 105:1494\u20131506. https:\/\/doi.org\/10.3324\/haematol.2019.243543","journal-title":"Haematologica"},{"key":"608_CR66","doi-asserted-by":"publisher","unstructured":"Peschke B, Keller CW, Weber P, Quast I, L\u00fcnemann JD (2017) Fc-Galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity. Front Immunol 8. https:\/\/doi.org\/10.3389\/fimmu.2017.00646","DOI":"10.3389\/fimmu.2017.00646"},{"key":"608_CR67","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3389\/fphar.2020.00443","volume":"11","author":"M Piris-Villaespesa","year":"2020","unstructured":"Piris-Villaespesa M, Alvarez-Twose I (2020) Systemic mastocytosis: following the tyrosine kinase inhibition roadmap. Front Pharmacol 11:443\u2013443. https:\/\/doi.org\/10.3389\/fphar.2020.00443","journal-title":"Front Pharmacol"},{"key":"608_CR68","unstructured":"Pollyea DA, Altman JK, Bhatt VR, Bixby D, Carraway H, Fathi AT, Foran JM, Goyo I, Hall AC, Jacoby M, Jonas BA, Lancet J, Mangan J, Mannis G, Marucci G, Mims A, Neff J, Nejati R, Olin R, Patel P, Percival M-E, Perl A, Przespolewski A, Rao D, Ravandi F, Shami PJ, Stone RM, Strickland SA, Sweet K, Tallman MS, Thota S, Vachhani P (2022) Acute myeloid leukemia \u2013 version 1.2022. NCCN clinical practice guidelines in oncology"},{"key":"608_CR69","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3390\/cancers12071823","volume":"12","author":"I Proietti","year":"2020","unstructured":"Proietti I, Skroza N, Michelini S, Mambrin A, Balduzzi V, Bernardini N, Marchesiello A, Tolino E, Volpe S, Maddalena P, Di Fraia M, Mangino G, Romeo G, Potenza C (2020) BRAF inhibitors: molecular targeting and immunomodulatory actions. Cancer 12:1823. https:\/\/doi.org\/10.3390\/cancers12071823","journal-title":"Cancer"},{"key":"608_CR70","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1182\/blood.2019000854","volume":"134","author":"A Quinquenel","year":"2019","unstructured":"Quinquenel A, Fornecker LM, Letestu R, Ysebaert L, Fleury C, Lazarian G, Dilhuydy MS, Nollet D, Guieze R, Feugier P, Roos-Weil D, Willems L, Michallet AS, Delmer A, Hormigos K, Levy V, Cymbalista F, Baran-Marszak F (2019) Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood 134:641\u2013644. https:\/\/doi.org\/10.1182\/blood.2019000854","journal-title":"Blood"},{"key":"608_CR71","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1182\/blood.2020008553","volume":"136","author":"S Reinke","year":"2020","unstructured":"Reinke S, Br\u00f6ckelmann PJ, Iaccarino I, Garcia-Marquez M, Borchmann S, Jochims F, Kotrova M, Pal K, Br\u00fcggemann M, Hartmann E, Sasse S, Kobe C, Mathas S, Soekler M, Keller U, Bormann M, Zimmermann A, Richter J, Fuchs M, von Tresckow B, Borchmann P, Schl\u00f6\u00dfer H, von Bergwelt-Baildon M, Rosenwald A, Engert A, Klapper W (2020) Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood 136:2851\u20132863. https:\/\/doi.org\/10.1182\/blood.2020008553","journal-title":"Blood"},{"key":"608_CR72","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood.2019000932","volume":"135","author":"A Reiter","year":"2020","unstructured":"Reiter A, George TI, Gotlib J (2020) New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. Blood 135:1365\u20131376. https:\/\/doi.org\/10.1182\/blood.2019000932","journal-title":"Blood"},{"key":"608_CR73","doi-asserted-by":"publisher","unstructured":"Romano A, Storti P, Marchica V, Scandura G, Notarfranchi L, Craviotto L, Di Raimondo F, Giuliani N (2021) Mechanisms of action of the new antibodies in use in multiple myeloma. Front Oncol 11. https:\/\/doi.org\/10.3389\/fonc.2021.684561","DOI":"10.3389\/fonc.2021.684561"},{"key":"608_CR74","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.1039\/c0cs00203h","volume":"40","author":"NR Rose","year":"2011","unstructured":"Rose NR, McDonough MA, King ON, Kawamura A, Schofield CJ (2011) Inhibition of 2-oxoglutarate dependent oxygenases. Chem Soc Rev 40:4364\u20134397. https:\/\/doi.org\/10.1039\/c0cs00203h","journal-title":"Chem Soc Rev"},{"key":"608_CR75","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","volume":"103","author":"R Roskoski Jr","year":"2016","unstructured":"Roskoski R Jr (2016) Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res 103:26\u201348. https:\/\/doi.org\/10.1016\/j.phrs.2015.10.021","journal-title":"Pharmacol Res"},{"key":"608_CR76","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","volume":"11","author":"F Rossari","year":"2018","unstructured":"Rossari F, Minutolo F, Orciuolo E (2018) Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol 11:84. https:\/\/doi.org\/10.1186\/s13045-018-0624-2","journal-title":"J Hematol Oncol"},{"key":"608_CR77","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","volume":"123","author":"D Rossi","year":"2014","unstructured":"Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Fam\u00e0 R, Rasi S, Monti S, Deambrogi C, De Paoli L, Wang J, Gattei V, Guarini A, Fo\u00e0 R, Rabadan R, Gaidano G (2014) Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 123:2139\u20132147. https:\/\/doi.org\/10.1182\/blood-2013-11-539726","journal-title":"Blood"},{"key":"608_CR78","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1182\/asheducation-2013.1.324","volume":"2013","author":"RF Schlenk","year":"2013","unstructured":"Schlenk RF, D\u00f6hner H (2013) Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia. Hematology 2013:324\u2013330. https:\/\/doi.org\/10.1182\/asheducation-2013.1.324","journal-title":"Hematology"},{"key":"608_CR79","unstructured":"Shah NP, Bhatia R, Altman JK, Amaya M, Berman E, Collins RH, Curtin PT, DeAngelo DJ, Gotlib J, Hobbs G, Maness L, Mead M, Metheny L, Mohan S, Moore JO, Oehler V, Patnaik M, Pratz K, Pusic I, Rose MG, Smith BD, Sweet KL, Talpaz M, Tanaka TN, Thompson J, Vaugh J, Welborn J, Yang DT (2022) Chronic myeloid leukemia \u2013 version 3.2022. NCCN clinical practice guidelines in oncology"},{"key":"608_CR80","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/bloodadvances.2020003423","volume":"5","author":"SS Sk\u00e5nland","year":"2021","unstructured":"Sk\u00e5nland SS, Mato AR (2021) Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. Blood Adv 5:334\u2013343. https:\/\/doi.org\/10.1182\/bloodadvances.2020003423","journal-title":"Blood Adv"},{"key":"608_CR81","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/0092-8674(93)90361-s","volume":"73","author":"CA Smith","year":"1993","unstructured":"Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E, Sutherland GR, Brannan CI, Copeland NG, Jenkins NA et al (1993) CD30 antigen, a marker for Hodgkin\u2019s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349\u20131360. https:\/\/doi.org\/10.1016\/0092-8674(93)90361-s","journal-title":"Cell"},{"key":"608_CR82","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/cancers14010087","volume":"14","author":"A Sochacka-\u0106wik\u0142a","year":"2022","unstructured":"Sochacka-\u0106wik\u0142a A, M\u0105czy\u0144ski M, Regiec A (2022) FDA-approved drugs for hematological malignancies \u2013 the last decade review. Cancer 14:87. https:\/\/doi.org\/10.3390\/cancers14010087","journal-title":"Cancer"},{"key":"608_CR83","unstructured":"Staber P (2022) Molekulare H\u00e4matologie. Zielgerichtete Therapie bei h\u00e4matologischen Neoplasien. https:\/\/www.medmedia.at\/mol-haema\/. Accessed 14 July 2022"},{"key":"608_CR84","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","volume":"123","author":"S Stilgenbauer","year":"2014","unstructured":"Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, D\u00f6hner K, B\u00fchler A, B\u00f6ttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, J\u00e4ger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, D\u00f6hner H (2014) Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 123:3247\u20133254. https:\/\/doi.org\/10.1182\/blood-2014-01-546150","journal-title":"Blood"},{"key":"608_CR85","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cdtm.2018.02.001","volume":"4","author":"R-F Sun","year":"2018","unstructured":"Sun R-F, Yu Q-Q, Young KH (2018) Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies. Chronic Dis Transl Med 4:29\u201344. https:\/\/doi.org\/10.1016\/j.cdtm.2018.02.001","journal-title":"Chronic Dis Transl Med"},{"key":"608_CR86","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues, revised","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, revised, 4th edn. International Agency for Research on Cancer, Lyon","edition":"4"},{"key":"608_CR87","doi-asserted-by":"publisher","first-page":"86","DOI":"10.37349\/ent.2021.00008","volume":"1","author":"K Tariq","year":"2021","unstructured":"Tariq K, Luikart BW (2021) Striking a balance: PIP(2) and PIP(3) signaling in neuronal health and disease. Explor Neuroprotective Ther 1:86\u2013100. https:\/\/doi.org\/10.37349\/ent.2021.00008","journal-title":"Explor Neuroprotective Ther"},{"key":"608_CR88","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","volume":"104","author":"E Tausch","year":"2019","unstructured":"Tausch E, Close W, Dolnik A, Bloehdorn J, Chyla B, Bullinger L, D\u00f6hner H, Mertens D, Stilgenbauer S (2019) Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica 104:e434\u2013e437. https:\/\/doi.org\/10.3324\/haematol.2019.222588","journal-title":"Haematologica"},{"key":"608_CR89","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40487-018-0091-5","volume":"7","author":"X Thomas","year":"2019","unstructured":"Thomas X (2019) Acute promyelocytic leukemia: a history over 60 years-from the Most malignant to the most curable form of acute leukemia. Oncol Ther 7:33\u201365. https:\/\/doi.org\/10.1007\/s40487-018-0091-5","journal-title":"Oncol Ther"},{"key":"608_CR90","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","volume":"364","author":"E Tiacci","year":"2011","unstructured":"Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Fo\u00e0 R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305\u20132315. https:\/\/doi.org\/10.1056\/NEJMoa1014209","journal-title":"N Engl J Med"},{"key":"608_CR91","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa2031298","volume":"384","author":"E Tiacci","year":"2021","unstructured":"Tiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani PL, Ascani S, Perriello VM, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Fo\u00e0 R, Visani G, Zaja F, Falini B (2021) Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia. N Engl J Med 384:1810\u20131823. https:\/\/doi.org\/10.1056\/NEJMoa2031298","journal-title":"N Engl J Med"},{"key":"608_CR92","doi-asserted-by":"publisher","first-page":"82","DOI":"10.12688\/f1000research.13167.1","volume":"7","author":"W Vainchenker","year":"2018","unstructured":"Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN (2018) JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Res 7:82. https:\/\/doi.org\/10.12688\/f1000research.13167.1","journal-title":"F1000Res"},{"key":"608_CR93","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1097\/HS9.0000000000000536","volume":"5","author":"P Valent","year":"2021","unstructured":"Valent P, Orfao A, Kubicek S, Staber P, Haferlach T, Deininger M, Kollmann K, Lion T, Virgolini I, Winter G, Hantschel O, Kenner L, Zuber J, Grebien F, Moriggl R, Hoermann G, Hermine O, Andreeff M, Bock C, Mughal T, Constantinescu SN, Kralovics R, Sexl V, Skoda R, Superti-Furga G, J\u00e4ger U (2021) Precision medicine in hematology 2021: definitions, tools, perspectives, and open questions. HemaSphere 5:e536\u2013e536. https:\/\/doi.org\/10.1097\/HS9.0000000000000536","journal-title":"HemaSphere"},{"key":"608_CR94","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","volume":"9","author":"NWCJ van de Donk","year":"2018","unstructured":"van de Donk NWCJ, Usmani SZ (2018) CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol 9:2134\u20132134. https:\/\/doi.org\/10.3389\/fimmu.2018.02134","journal-title":"Front Immunol"},{"key":"608_CR95","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1038\/bcj.2017.85","volume":"7","author":"CA van der Weyden","year":"2017","unstructured":"van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM (2017) Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J 7:e603\u2013e603. https:\/\/doi.org\/10.1038\/bcj.2017.85","journal-title":"Blood Cancer J"},{"key":"608_CR96","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1365-2567.2007.02752.x","volume":"123","author":"JA Walker","year":"2008","unstructured":"Walker JA, Smith KGC (2008) CD22: an inhibitory enigma. Immunology 123:314\u2013325. https:\/\/doi.org\/10.1111\/j.1365-2567.2007.02752.x","journal-title":"Immunology"},{"key":"608_CR97","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D (2012) CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 1:36. https:\/\/doi.org\/10.1186\/2162-3619-1-36","journal-title":"Exp Hematol Oncol"},{"key":"608_CR98","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","volume":"19","author":"P Wang","year":"2020","unstructured":"Wang P, Wang Z, Liu J (2020) Role of HDACs in normal and malignant hematopoiesis. Mol Cancer 19:5. https:\/\/doi.org\/10.1186\/s12943-019-1127-7","journal-title":"Mol Cancer"},{"key":"608_CR99","doi-asserted-by":"publisher","unstructured":"W\u00e4sterlid T, Cavelier L, Haferlach C, Konopleva M, Fr\u00f6hling S, \u00d6stling P, Bullinger L, Fioretos T, Smedby KE (2022) Application of precision medicine in clinical routine in haematology \u2013 challenges and opportunities. J Intern Med. https:\/\/doi.org\/10.1111\/joim.13508","DOI":"10.1111\/joim.13508"},{"key":"608_CR100","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-017-0516-x","volume":"10","author":"G Wei","year":"2017","unstructured":"Wei G, Wang J, Huang H, Zhao Y (2017) Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol 10:150. https:\/\/doi.org\/10.1186\/s13045-017-0516-x","journal-title":"J Hematol Oncol"},{"key":"608_CR101","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","volume":"35","author":"T Wen","year":"2021","unstructured":"Wen T, Wang J, Shi Y, Qian H, Liu P (2021) Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances. Leukemia 35:312\u2013332. https:\/\/doi.org\/10.1038\/s41375-020-01072-6","journal-title":"Leukemia"},{"key":"608_CR102","doi-asserted-by":"publisher","first-page":"6293","DOI":"10.7150\/thno.57177","volume":"11","author":"JM White","year":"2021","unstructured":"White JM, Escorcia FE, Viola NT (2021) Perspectives on metals-based radioimmunotherapy (RIT): moving forward. Theranostics 11:6293\u20136314. https:\/\/doi.org\/10.7150\/thno.57177","journal-title":"Theranostics"},{"key":"608_CR103","doi-asserted-by":"crossref","unstructured":"Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brandner D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato AR, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye CJ (2022) Chronic lymphocytic leukemia\/small lymphocytic lymphoma \u2013 version 2.2022. NCCN clinical practice guidelines in oncology","DOI":"10.6004\/jnccn.2022.0031"},{"key":"608_CR104","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1200\/jco.2002.11.017","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262\u20133269. https:\/\/doi.org\/10.1200\/jco.2002.11.017","journal-title":"J Clin Oncol"},{"key":"608_CR105","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","volume":"120","author":"JA Woyach","year":"2012","unstructured":"Woyach JA, Johnson AJ, Byrd JC (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120:1175\u20131184. https:\/\/doi.org\/10.1182\/blood-2012-02-362624","journal-title":"Blood"},{"key":"608_CR106","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC (2014) Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N Engl J Med 370:2286\u20132294. https:\/\/doi.org\/10.1056\/NEJMoa1400029","journal-title":"N Engl J Med"},{"key":"608_CR107","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17\u201330. https:\/\/doi.org\/10.1016\/j.ccr.2010.12.014","journal-title":"Cancer Cell"},{"key":"608_CR108","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/onc.2009.392","volume":"29","author":"L Yang","year":"2010","unstructured":"Yang L, Xie G, Fan Q, Xie J (2010) Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 29:469\u2013481. https:\/\/doi.org\/10.1038\/onc.2009.392","journal-title":"Oncogene"},{"key":"608_CR109","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hern\u00e1ndez-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T (2014) BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 26:428\u2013442. https:\/\/doi.org\/10.1016\/j.ccr.2014.07.006","journal-title":"Cancer Cell"},{"key":"608_CR110","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","volume":"9","author":"D Zahavi","year":"2020","unstructured":"Zahavi D, Weiner L (2020) Monoclonal antibodies in cancer therapy. Antibodies (Basel) 9:34","journal-title":"Antibodies (Basel)"},{"key":"608_CR111","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00432-021-03833-x","volume":"148","author":"PL Zinzani","year":"2022","unstructured":"Zinzani PL, Minotti G (2022) Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 148:177\u2013190. https:\/\/doi.org\/10.1007\/s00432-021-03833-x","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Handbook of Experimental Pharmacology","Precision Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2022_608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T12:04:41Z","timestamp":1693569881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2022_608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783031400469","9783031400476"],"references-count":111,"URL":"https:\/\/doi.org\/10.1007\/164_2022_608","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"22 August 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}